Navigation Links
Lytix Closes USD 10.4 Million Funding Round
Date:1/22/2009

TROMS0, Norway, January 22 /PRNewswire/ -- The Scandinavian-based drug development company Lytix Biopharma today announced the closure of a successful funding round to a total value of 73 million NOK (US$ 10.4 million), the proceeds of which will fund the early-stage clinical development of two novel drugs.

Lytix develops novel lytic peptide drugs for the treatment of resistant bacterial and fungal infections, as well as first-in-class oncology treatments - both areas with high unmet medical needs. The Company was established in 2003 to commercialise world-class research in the field of lytic peptides, having spun out by scientists working in the University Hospital and University of Tromso in Norway.

Lytix Biopharma CEO Gunnar Saelid commented, "The Company has made significant progress in the last year, initiating full preclinical development activities for two important projects. LTX-109 is a novel antimicrobial compound that is effective against a broad range of pathogens. Indeed it is so effective, that although the initial formulation is for the treatment of skin infections, we envisage several other indications such as nail fungal infections, acne and oropharyngeal candidaisis. In oncology, LTX-315 (Oncopore(TM)) is a product aimed at the treatment of solid tumours, potentially in combination with existing therapies. Oncopore(TM) is currently in preclinical development and has proven efficacy across a range of 40 tumour cell lines, including lines resistant to established chemotherapy. In vivo studies in syngeneic mice demonstrate a potential for a rapid induction of tumour necrosis, and a complete and stable tumour response mediated by the immune-system. Both LTX-109 and LTX-315 will enter the clinical phases during the latter half of 2009."

In order to capitalise on the commercial potential that lies in this development pipeline, Lytix has successfully raised working capital through a shares issue totalling 73 million NOK to fund the early-stage clinical development. Chairman of Board, Knut Eidissen, added: "We are truly excited to be involved with such innovative projects - if we are successful we can potentially cure some very sick patients and save lives. It goes without saying that the commercial upside is significant for a company like ours, which aims to outlicense rights and form joint-venture partnerships with larger pharmaceutical companies. The interest shown in our company, even in these turbulent financial times, further strengthens our belief in the value of our pipeline."

    Corporate Inquiries

    Gunnar Saelid, CEO
    Lytix Biopharma AS
    P.O. Box 6447, Tromso Research Park, N-9294 Tromso, Norway
    Tel +47-911-92-330, Email: gunnar.salid@lytixbiopharma.com



'/>"/>
SOURCE Lytix Biopharma AS
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ZyGEM and Advalytix Partner to Produce Innovative DNA Extraction Products
2. Singulex Closes $19 Million Financing Round
3. Karolinska Development Closes Fully Subscribed New Share Issue
4. Concentric Medical Closes on $15 Million Financing
5. Intradigm Closes Final Tranche of $21.4 Million Series B Financing
6. Diagnoplex Closes CHF10 Million ($8.3 Million) Series A Financing
7. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
8. MicroPhage Closes Latest Financing
9. Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
10. CVBT Closes Clinical Development Agreement for Coronary Heart Disease Drug Candidate
11. Starfish Ventures Closes Australias Largest Venture Capital Fund With $185 Million Tech Fund
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... BARCELONA, Spain , Dec. 8, 2016  Anaconda ... on the development of the next generation neuro-thrombectomy system ... the appointment of Tudor G. Jovin, MD to join ... to serve as a strategic network of scientific and ... progresses the development of the ANCD BRAIN ® ...
(Date:12/8/2016)... CA (PRWEB) , ... December 08, 2016 , ... ... as finalists in the World Technology Awards. uBiome is one of just six ... across all categories. , In addition to uBiome, companies nominated as finalists in ...
(Date:12/8/2016)... Dec. 8, 2016 Soligenix, Inc. (OTCQB: SNGX) ... on developing and commercializing products to treat rare diseases ... that it will be hosting an Investor Webcast Event ... the origins of innate defense regulators (IDRs) as a ... oral mucositis and the recently announced and published Phase ...
(Date:12/8/2016)... Eutilex Co. Ltd. today announced that it ... A financing. This financing round included participation from DS ... Bio Angel. This new funding brings the total capital ... since its founding in 2015. The ... commercialization of its immuno-oncology programs, expand its R&D capabilities ...
Breaking Biology Technology:
(Date:12/2/2016)... 1, 2016 The report "Biometric ... Future Technology (Iris Recognition System), Vehicle Type (Passenger ... Forecast to 2021", published by MarketsandMarkets, the market ... 2016, and is projected to grow to USD ... 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/29/2016)... Lithuania , Nov. 29, 2016 /PRNewswire/ ... biometric identification and object recognition technologies, today ... (SDK) for fingerprint recognition solutions that run ... a fingerprint template using less than 128KB ... in compact devices that have limited on-board ...
(Date:11/22/2016)... MINNETONKA, Minn. , Nov. 22, 2016   ... that supports the entire spectrum of clinical research, is ... by Medical LiveWire Healthcare and Life Sciences Awards ... This award caps off an unprecedented year of recognition ... clinical trials for over 15 years. iMedNet ...
Breaking Biology News(10 mins):